このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours (LET-PT)

2026年11月10日 更新者:Universitaire Ziekenhuizen KU Leuven

Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours - a Prospective Study

The goal of this prospective study is to evaluate whether incorporating linear energy transfer (LET) and variable relative biological effectiveness (RBE) into proton therapy (PT) treatment planning is feasible and may reduce treatment-related adverse events in patients with primary brain tumours. For all participants, the LET distribution and the McNamara variable RBE model will be evaluated during treatment planning. Where feasible, the proton therapy plan will be optimised to reduce areas of high LET in healthy brain tissue while maintaining adequate treatment of the tumour. Participants will undergo standard clinical and MRI follow-up and will additionally be asked to complete quality-of-life questionnaires at several time points.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

In clinical treatment planning, a constant RBE of 1.1 is assumed. However, proton RBE depends on several factors, including linear energy transfer (LET). RBE uncertainties can result in unexpected toxicities in patients treated with proton therapy (PT) for primary brain tumours. To address RBE uncertainties in PT treatment planning, this prospective trial evaluates the feasibility and outcomes of incorporating LET distribution information and the McNamara variable RBE model into treatment planning for patients diagnosed with primary brain tumours. The primary objective is to evaluate the effect of this planning strategy on the incidence of treatment-related imaging abnormalities (TRIA) in healthy brain tissue after PT. Outcomes will be compared with those of a historical cohort of patients who received PT at the same centre before the introduction of the novel planning strategy.

Secondary objectives are:

  • To gain further insight into the feasibility of an LET-based treatment planning method in primary brain tumours.
  • To assess additional side effects after PT for primary brain tumours.
  • To investigate the response of primary brain tumours after PT.

Participants will undergo standard clinical and MRI follow-up and will complete quality-of-life questionnaires at predefined time points.

研究の種類

介入

入学 (推定)

100

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Patients diagnosed with primary brain tumours including, but not limited to:

    1. Low-grade glioma including: paediatric-type diffuse low-grade glioma, astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted
    2. Ependymal tumours
    3. Tumours of the sellar region including, but not limited to, craniopharyngioma
    4. Medulloblastoma and other embryonal tumours, including, but not limited to, atypical teratoid/rhabdoid tumours
    5. Meningioma
    6. Primary neuroectodermal tumours
    7. Germ cell tumours
    8. Choroid plexus tumours
    9. Pineal tumours
  2. Both adults and children are eligible for inclusion

  3. Referred to PARTICLE for proton therapy treatment

  4. Treatment with PT approved and reimbursed by RIZIV/INAMI

  5. Ability of patient and/or parents or legal guardian to sign informed consent

Exclusion Criteria:

  1. Mixed photon-proton planning
  2. Re-irradiation
  3. Contraindication for MRI (claustrophobia, metallic implants like pacemaker/ICD/neurostimulator)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:LET-based evaluation in treatment planning

Treatment planning will initially be performed according to standard clinical practice using an RBE-weighted dose based on a fixed RBE of 1.1, expressed in Gy(RBE). The resulting plan will then undergo additional evaluation using LET distributions and variable RBE-weighted dose distributions calculated with the McNamara model. If areas of high LET or high estimated biological dose are identified in healthy brain tissue, the treatment plan may be adjusted to reduce these areas while maintaining adequate target coverage and compliance with standard dose constraints for organs at risk. LET and variable RBE evaluation will be used as auxiliary planning metrics and will not replace standard clinical dose evaluation.

他の名前:
  • 陽子線治療
  • LET-based treatment evaluation
  • LET-based treatment planning
  • variable RBE-based treatment evaluation
  • variable RBE-based treatment planning

MRI assessments according to routine follow-up for TRIA and response assessment.

Assessing QoL in adults (aged > 25 years) using the EORTC QLQ-C30 and EORTC QLQ-BN20 questionnaires. Assessing QoL in children (aged ≤ 25 years) using the age-appropriate PedsQL Brain Tumour Module.

Evaluating the incidence of CNS toxicities using the CTCAE v5.0

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
The occurrence of Treatment-Related Imaging Abnormality (TRIA) CTCAE version 5.0 grade ≥ 1.
時間枠:Up to 12 months after treatment. MRI at 6 and 12 months after completion of proton therapy treatment for assessment of TRIA.

TRIA is defined as any new or increased abnormality observed on post-contrast T1-weighted, T2-weighted, or T2-weighted-FLAIR MRI sequences, absent on the corresponding pre-radiotherapy (and post-surgical, if surgery preceded radiotherapy) imaging, not consistent with post-surgical changes or unambiguous tumour progression, with confirmation on subsequent follow-up MRI recommended to substantiate this diagnosis. TRIA will be scored as a CNS necrosis adverse event according to the CTCAE scale version 5.0.

Up to 12 months after treatment. MRI at 6 and 12 months after completion of proton therapy treatment for assessment of TRIA.

二次結果の測定

結果測定
メジャーの説明
時間枠
Treatment planning feasibility: number of plan iterations.
時間枠:Baseline (during treatment planning).

Evaluating the number of plan iterations required for a satisfactory LET-based treatment plan, acting as a surrogate for additional planning time required in the treatment planning workflow.

Baseline (during treatment planning).
Treatment planning feasibility: number of plans requiring LET-based replanning.
時間枠:Baseline (during treatment planning).

Evaluating the number of RBE1.1-based plans in need of a replanning to a LET-based treatment plan.

Baseline (during treatment planning).
Treatment planning feasibility: planning effort
時間枠:Baseline (once before and once after LET-based replanning).

Evaluating the effort needed for replanning using the National Aeronautics and Space Administration Task Load Index (NASA-TLX). Workload is rated on six subscales (mental demand, physical demand, temporal demand, performance, effort and frustration), each scored from 0 to 20; the overall score is the mean of the six subscales (0-20). Higher scores indicate a higher workload (worse outcome).

Baseline (once before and once after LET-based replanning).
CNS toxicities
時間枠:Baseline; during proton therapy in weeks 1, 2, 3, 4, 5 and 6; and at 3, 6, 9 and 12 months after proton therapy.

Evaluating the incidence of CNS toxicities graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grades range from 1 (mild) to 5 (death related to adverse event); higher grades indicate a worse outcome.

Baseline; during proton therapy in weeks 1, 2, 3, 4, 5 and 6; and at 3, 6, 9 and 12 months after proton therapy.
Quality of life assessments: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30).
時間枠:Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.

Assessing QoL in adults (aged > 25 years) using the EORTC QLQ-C30. Scores range from 0 to 100. For the global health status and functional scales, higher scores indicate better quality of life and functioning; for the symptom scales, higher scores indicate a higher symptom burden (worse outcome).

Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
Quality of life assessments: European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - Brain Neoplasm (20 items) (EORTC QLQ-BN20).
時間枠:Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.

Assessing QoL in adults (aged >25 years) using the EORTC QLQ-BN20. Scores range from 0 to 100; higher scores indicate a higher symptom burden (worse outcome).

Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
Quality of life assessments: Pediatric Quality of Life Inventory (PedsQL) Brain Tumor Module.
時間枠:Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.

Assessing QoL in children (aged ≤ 25 years) using the age-appropriate PedsQL Brain Tumor Module. Scores range from 0 to 100; higher scores indicate better health-related quality of life.

Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
Response assessment
時間枠:At 6 and 12 months after proton therapy.

Number of participants per response category (complete response, partial response, stable disease, progressive disease) according to the Response Assessment in Neuro-Oncology (RANO) criteria.

At 6 and 12 months after proton therapy.
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum LETd in healthy brain tissue.
時間枠:Baseline (after treatment planning).

Comparing the maximum dose-averaged linear energy transfer (LETd), reported as D1% (in keV/µm), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan.

Baseline (after treatment planning).
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum constant RBE-weighted dose in healthy brain tissue.
時間枠:Baseline (after treatment planning).

Comparing the maximum constant RBE-weighted dose (RBE 1.1), reported as D0.03cc (in Gy(RBE)), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan.

Baseline (after treatment planning).
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum variable RBE-weighted dose in healthy brain tissue.
時間枠:Baseline (after treatment planning).

Comparing the maximum McNamara variable RBE-weighted dose, reported as D0.03cc (in Gy(RBE)), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan.

Baseline (after treatment planning).
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Target coverage.
時間枠:Baseline (after treatment planning).

Comparing target coverage, reported as [CTV D98%] (in Gy(RBE)), between the RBE1.1-based plan and the LET-based plan.

Baseline (after treatment planning).

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月1日

一次修了 (推定)

2028年4月1日

研究の完了 (推定)

2029年4月1日

試験登録日

最初に提出

2026年10月21日

QC基準を満たした最初の提出物

2026年11月10日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • S71405

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。